SCHEMBL1959691

SCHEMBL1959691

CN1CCN(Nc2ccc(S(=O)(=O)NC(=O)c3ccccc3Oc3cccc4[nH]ccc34)cc2[N+](=O)[O-])CC1

nearest known ligand 0.67

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2507851 0.88 BCL2 (0.54) BCL2
SCHEMBL1956705 0.88 BCL2 (0.61) BCL2
SCHEMBL2730313 0.87 BCL2 (0.60) BCL2
SCHEMBL1958105 0.85 BCL2 (0.59) BCL2
SCHEMBL29657285 0.83 BCL2 (0.61) BCL2
SCHEMBL2725866 0.83 BCL2 (0.61) BCL2
SCHEMBL1957815 0.82 — —
SCHEMBL2829453 0.82 BCL2 (0.70) BCL2
SCHEMBL1743273 0.80 FLT1 (0.51) —
SCHEMBL2484548 0.79 BCL2 (0.54) BCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2507229-A1 SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES Abbott Laboratories (US) 2012-10-10 — — EP disclosed
WO-2011068561-A1 SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES ABBOTT LABORATORIES (US) 2011-06-09 — — WO disclosed
Send feedback